pegylated interferon alfa
Phase 3Biologic
Merck & Co.pegylated interferon alfa is one of 87 biologic programs targeting Metastatic Melanoma. It is currently in Phase 3.
2
Indications
11
Total Trials
1
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
71 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Hepsera
GileadApproved
PEG-Intron
Merck & Co.Phase 3
Actos
TakedaApproved
Glucophage
EMD SeronoApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Opdivo
Bristol-Myers SquibbPhase 2
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Azvudine
HHenan Genuine Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis4 trials
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
Unknown status·—·Phase 2·NCT03105310·20 enrolled
Show 1 more trial
The Clinical Cure Project of Chronic Hepatitis B in China
Active, not recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT04035837·30,000 enrolled
Melanoma2 trials
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00006249·1,258 enrolled
Metastatic Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pegylated interferon alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company